SpineThera Announces Results for SX600 from its SALIENT Phas

PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced promis...

Related Keywords

Adelaide , South Australia , Australia , Minnesota , United States , University Of Adelaide , Turkey , Turk , Jeff Missling , Clinical Research , Initiative On Methods , Spinethera Inc , Oswestry Disability Index , Spain Assessment , Clinical Trials , Guy Ludbrook , Royal Adelaide Hospital , Acute Care Medicine , Principal Investigator , Bill Houghton , Chief Medical Officer , Medical Director , Medical Alley ,